3-Year Return on Invested Incremental Capital (3-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 3-year.
Neuland Laboratories's 3-Year ROIIC % for the quarter that ended in Mar. 2026 was 19.36%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
The industry rank for Neuland Laboratories's 3-Year ROIIC % or its related term are showing as below:
NSE:NEULANDLAB's 3-Year ROIIC % is ranked better than 69.7% of 944
companies
in the Drug Manufacturers industry
Industry Median: 3.72
vs NSE:NEULANDLAB: 19.36
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
Neuland Laboratories 3-Year ROIIC % Related Terms
Neuland Laboratories 3-Year ROIIC % Historical Data
* Premium members only.
The historical data trend for Neuland Laboratories's 3-Year ROIIC % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NSE:NEULANDLAB vs ZTS, UTHR: 3-Year ROIIC % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Neuland Laboratories's 3-Year ROIIC %, along with its competitors' market caps and 3-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Neuland Laboratories 3-Year ROIIC % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Neuland Laboratories's 3-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where Neuland Laboratories's 3-Year ROIIC % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 3-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
Neuland Laboratories (NSE:NEULANDLAB) has a 3-Year ROIIC % of 19.36 as of Mar. 2026. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Neuland Laboratories and its competitors. This is 10% above median its historical median of 17.54. According to the industry distribution chart, Neuland Laboratories ranks #286 out of 944 companies in the Drug Manufacturers industry, placing it in the top 30.3%.
Is Neuland Laboratories' 3-Year ROIIC % too high?
Neuland Laboratories' current 3-Year ROIIC % of 19.36 is 10% above median its 10-year median of 17.54. The Drug Manufacturers industry median 3-Year ROIIC % is 3.72. Neuland Laboratories' value of 19.36 is 420.4% above this industry median. Based on the distribution chart, Neuland Laboratories ranks #286 out of 944 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Neuland Laboratories has a GF Score™ of 92/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Neuland Laboratories' 3-Year ROIIC % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Neuland Laboratories ranks #286 out of 944 companies for 3-Year ROIIC %. This puts Neuland Laboratories in the upper half of its industry. The industry median 3-Year ROIIC % is 3.72. Neuland Laboratories' value of 19.36 is 420.4% above this benchmark. While the company's 10-year median is 17.54 vs. the industry median of 3.72, Neuland Laboratories has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year ROIIC % for a Drug Manufacturers company?
The median 3-Year ROIIC % among Drug Manufacturers companies is 3.72, based on 944 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year ROIIC % significantly above this median, while those in the bottom quartile fall well below. However, 3-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Neuland Laboratories's current 3-Year ROIIC % of 19.36 is 420.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year ROIIC % mean?
A high 3-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Neuland Laboratories and its competitors. For the Drug Manufacturers industry, the median 3-Year ROIIC % is 3.72 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Neuland Laboratories's current 3-Year ROIIC % is 19.36, which is 10% above median its own 10-year median of 17.54. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Neuland Laboratories stock overvalued right now?
Based on GuruFocus' analysis, Neuland Laboratories (NSE:NEULANDLAB) is currently considered Modestly Overvalued. The stock's GF Value™ is ₹16,543.82, compared to a current price of ₹18,956.00 — trading 14.6% above its estimated fair value. The current 3-Year ROIIC % is 19.36, which is 10% above median its 10-year median of 17.54 and 420.4% above the Drug Manufacturers industry median of 3.72. Neuland Laboratories' overall GF Score™ is 92/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year ROIIC % calculated?
3-Year ROIIC % is calculated from a company's financial statements. For Neuland Laboratories (NSE:NEULANDLAB), the current 3-Year ROIIC % is 19.36 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Neuland Laboratories (NSE:NEULANDLAB) Overvalued in 2026?
Based on GuruFocus' analysis, Neuland Laboratories stock appears to be overvalued.
The current stock price of ₹18,956.00 is trading 14.6% above its estimated GF Value™ of ₹16,543.82.
GuruFocus considers Neuland Laboratories to be Modestly Overvalued.
Key valuation signals for NSE:NEULANDLAB:
3-Year ROIIC %: 19.36 (10% above median its 10-year median of 17.54)
GF Value™: ₹16,543.82 vs. price of ₹18,956.00 (14.6% above fair value)
Industry Position: 420.4% above the Drug Manufacturers median (#286 of 944)
No single metric tells the full story. See the NSE:NEULANDLAB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Neuland Laboratories Ltd is engaged in the manufacturing and selling of bulk drugs and caters to both the domestic and international markets. It is an API contract development and manufacturing organization (CDMO), supporting biotechnology and pharmaceutical companies in the design, development, and manufacturing of complex active pharmaceutical ingredients (APIs). The company develops small molecules and peptides for clinical trials and beyond, with the capacity to scale up through every stage of the product lifecycle to commercial manufacturing. Geographically, the group derives maximum revenue from its customers in India, followed by Europe, the USA and North America, and the Rest of the world.
92GF Score
Get the complete analysis for NSE:NEULANDLAB
3-Year ROIIC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:NEULANDLAB has been successfully added to your 
